查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026930

介入性腫瘤學市場預測至2034年－按產品、適應症、手術類型、最終用戶和地區分類的全球分析

Interventional Oncology Market Forecasts to 2034 - Global Analysis By Product (Ablation Devices, Embolization Devices and Support Devices), Indication, Procedure Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球介入性腫瘤學市場規模將達到 31 億美元，並在預測期內以 8.8% 的複合年成長率成長，到 2034 年將達到 61 億美元。

在介入放射學領域，介入性腫瘤學專注於運用微創技術進行癌症的檢測和治療。這些手術利用透視、磁振造影（MRI）、電腦斷層掃描（CT）和超音波等影像技術來定位器械，並將標靶治療直接輸送到惡性腫瘤。

根據美國癌症協會的數據，男性一生中罹患乳癌的風險約為 1/833。因此，隨著乳癌負擔的加重，預計在預測期內介入腫瘤手術的數量將會增加，這將推動市場成長。

對微創治療方法的需求日益成長

在患者和醫療專業人員對微創手術需求不斷成長的推動下，介入性腫瘤治療正日益普及。與開放性手術相比，這些方法具有恢復時間更短、住院時間更短、併發症更少等優勢。因此，某些類型癌症的治療正擴大轉向介入性腫瘤技術。以患者為中心的醫療模式，即患者希望獲得恢復時間更短、副作用更少、生活品質更高的治療方法，與微創手術市場的成長趨勢不謀而合。

合格醫療技術人員短缺

熟練的檢查室專家短缺會影響醫療服務的品質。這些複雜的操作需要具備必要技能的專家才能準確、精確地完成，而缺乏此類專家可能會影響達到最佳治療效果所需的知識水平。在熟練人員稀缺的地區和醫療機構，患者可能難以獲得專業的介入性腫瘤治療服務。因此，這種服務取得方面的差異可能會影響患者接受微創癌症治療的機會。

擴大政府支持和償還政策

更完善的報銷指南和更大的政府支持有望促進介入性腫瘤治療市場的發展。經濟獎勵和擴大保險覆蓋範圍預計將鼓勵更多醫療機構提供此類療法，從而改善患者的就醫途徑。更完善的報銷規定將降低患者尋求介入癌症治療時面臨的經濟障礙。因此，更多患者將能夠接受這些治療，確保更廣泛的人群能夠獲得尖端、微創的癌症療法。

對醫療設備的嚴格監管

由於需要進行大量的測試、文件編制和合規程序以滿足嚴格的監管標準，開發用於介入腫瘤學的新型醫療設備成本極為高昂。這些飆升的研發成本可能會限制願意投資新技術研發的公司數量。雖然這些法規旨在保護患者，但它們也可能阻礙新型醫療設備和技術的市場推廣，可能延緩介入腫瘤療法的研發。

新冠疫情的感染疾病

由於擔心醫療機構內病毒感染，一些患者推遲了癌症治療，尤其是介入治療，甚至完全放棄了就醫。這種延誤可能阻礙了必要的癌症治療的及時啟動和持續進行。為了縮短住院時間並降低病毒感染風險，腫瘤科醫師和其他醫護人員可能調整了治療策略，例如優先使用全身性藥物和其他治療方法，而非介入性治療。

在預測期內，消融設備領域預計將佔據最大的市場佔有率。

由於消融設備為治療各種腫瘤提供了創傷較小的替代方案，預計其市場將迎來盈利發展。這些設備利用熱能、冷能或其他能源來源來破壞腫瘤，而非進行手術切除。消融設備廣泛應用於安寧療護、腫瘤縮小、腫瘤消融以及其他介入性腫瘤治療。與傳統手術相比，消融設備具有創傷小、恢復快、併發症少等優勢，使其成為部分癌症患者的理想選擇，從而推動了市場成長。

預計在預測期內，骨癌細分市場將呈現最高的複合年成長率。

預計在預測期內，骨癌細分市場將呈現最高的複合年成長率。骨癌的常規治療方法包括手術、化療，有時還包括放射線治療。然而，介入性腫瘤學技術在某些情況下可能有效，或可作為常規癌症治療的輔助手段。如果骨癌進展或引起併發症，介入治療可作為安寧療護的一部分。例如，介入性放射學手術，如腫瘤消融術（射頻消融術或冷凍消融），可用於治療疼痛和控制骨轉移相關的症狀。

市佔率最大的地區：

由於亞太地區癌症病例數量眾多，且部分國家癌症發生率較高，預計該地區將在預測期內佔據最大的市場佔有率。該地區的癌症發生率受多種因素影響，包括生活方式的改變、環境的變化以及癌症篩檢計畫的擴展。此外，結合磁振造影（MRI）、電腦斷層掃描（CT）和超音波等影像診斷技術與尖端設備相結合的介入性腫瘤學技術的運用，正在提高癌症治療的準確性、有效性和安全性，從而推動市場成長。

複合年成長率最高的地區：

預計北美地區在預測期內將呈現最高的複合年成長率。這是因為該地區完善的醫療保健體系、技術進步以及對微創癌症治療日益成長的需求是推動市場成長的主要因素。此外，癌症高發生率、該地區完善的醫療保健體系、技術進步以及對微創癌症治療日益成長的需求也是推動市場成長的主要因素。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球介入性腫瘤市場：依產品分類

  • 消融裝置
    • 冷凍消融裝置
    • 微波消融裝置
    • 射頻消融裝置
    • 其他消融裝置
  • 栓塞裝置
    • 非放射性栓塞劑
      • 微球
      • 細顆粒物
      • 塗層珠
      • 藥物釋放型微珠
    • 放射性栓塞劑
  • 輔助設備
    • 導管導引線
    • 微導管

第6章 全球介入性腫瘤市場：依適應症分類

  • 肝細胞癌
  • 骨癌
  • 腎癌
  • 肺癌
  • 神經內分泌腫瘤
  • 多形性膠質母細胞瘤
  • 脾腫大
  • 轉移性大腸直腸癌
  • 其他改編

第7章 全球介入性腫瘤市場：依手術類型分類

  • 經導管動脈放射性胚胎植入術
  • 經導管動脈化療栓塞術
  • 熱消融腫瘤
  • 非熱腫瘤消融
  • 經導管動脈栓塞術
  • 其他類型的技術

第8章 全球介入性腫瘤市場：依最終用戶分類

  • 門診手術中心
  • 研究和學術機構
  • 醫院
  • 其他最終用戶

第9章 全球介入性腫瘤市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • AngioDynamics Inc.
  • Cook Medical
  • HealthTronics Inc.
  • Boston Scientific Corporation
  • Medtronic PLC
  • Terumo Corporation
  • Becton, Dickinson and Company
  • Merit Medical Systems Inc.
  • Profound Medical Corp.
  • IceCure Medical
  • Siemens Healthineers
  • Teleflex Incorporated
  • Medtronic Plc.
  • Alpinion Medical Systems Co.
  • IMBiotechnologies
  • Interface Biomaterials BV
  • Monteris Medical
  • Baylis Medical
  • Mermaid Medicals
  • Trod Medical
Product Code: SMRC24746

According to Stratistics MRC, the Global Interventional Oncology Market is accounted for $3.1 billion in 2026 and is expected to reach $6.1 billion by 2034 growing at a CAGR of 8.8% during the forecast period. Within the area of interventional radiology, interventional oncology focuses on the use of minimally invasive methods for the detection and treatment of cancer. During these operations, imaging modalities including fluoroscopy, magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound are used to guide the positioning of tools and provide targeted therapies directly to malignancies.

According to the American Cancer Society, a man's lifetime risk of developing breast cancer is about 1 in 833. Hence, with the growing burden of breast cancer, interventional oncology procedures are expected to increase over the forecast period, which will drive growth in the market

Market Dynamics:

Driver:

Growing demand for minimally invasive therapeutics

Interventional oncology treatments are becoming more widely used as a result of patients' and healthcare professionals' growing demand for minimally invasive procedures. Compared to open operations, these methods provide quicker recovery periods, shorter hospital stays, and fewer problems. As a result, the treatment of some cancer types is increasingly moving toward interventional oncology techniques. The movement toward patient-centric care, in which patients look for therapies that provide shorter recovery periods, fewer side effects, and enhanced quality of life, is consistent with minimally invasive procedures which boost the market growth.

Restraint:

Lack of qualified laboratory personnel

The quality of care given might be jeopardized by a lack of skilled laboratory professionals. Professionals with the necessary skills are essential for carrying out these complex operations precisely and accurately, and a lack might impact the level of knowledge available to get the best results. Patients may have restricted access to specialist Interventional Oncology services in areas or healthcare settings where there is a shortage of skilled staff. Thus, the capacity of patients to get minimally invasive cancer therapies may be impacted by this gap in access.

Opportunity:

Increase in the government support and reimbursement policies

Better reimbursement guidelines and increased government assistance might propel the market for interventional oncology therapies forward. Better financial incentives and coverage are expected to encourage more healthcare providers to provide these therapies, increasing patient accessibility. Patients pursuing interventional cancer therapies may face less financial obstacles with improved reimbursement regulations. This may result in more patients having access to these treatments, guaranteeing that more people will have access to cutting-edge, minimally invasive cancer treatments.

Threat:

Stringent regulations for medical devices

Creating novel medical devices for interventional oncology may become quite expensive as a result of the considerable testing, paperwork, and compliance procedures needed to meet strict regulatory criteria. The number of businesses ready to invest in research and development for new technologies may be hampered by higher development expenses. Although the goal of these laws is to protect patients, they can also impede the introduction of novel devices and technologies into the market, which could postpone the development of interventional oncology therapies.

Covid-19 Impact

Fears of contracting the virus in medical settings caused some patients to postpone receiving cancer therapies, especially interventional procedures, or seeking medical assistance altogether. It's possible that this delay interfered with the timely start or continuation of essential cancer therapies. In order to reduce hospital stays or the risk of contracting the virus, oncologists and other healthcare professionals may have modified treatment strategies, preferring systemic medications or other forms of therapy over interventional procedures.

The ablation devices segment is expected to be the largest during the forecast period

Due to the fact that ablation devices provide less intrusive options for treating a variety of tumor types, the market for these devices is predicted to increase profitably. These devices destroy tumors by using heat, cold, or other energy sources instead of surgical excision. These ablation devices are used in palliative care, tumor reduction, and tumor ablation, among other interventional oncology therapies. Their advantages over traditional surgery, such as less invasiveness, faster recovery, and fewer complications, make them desirable options for some cancer patients and drive the market.

The osteosarcoma segment is expected to have the highest CAGR during the forecast period

The osteosarcoma segment is anticipated to witness the highest CAGR growth during the forecast period; surgery, chemotherapy, and sometimes radiation therapy are used in conjunction as the conventional treatment for osteosarcoma. Interventional oncology methods, however, could be useful in some situations or in addition to conventional cancer therapies. Palliative treatment may involve interventional therapies if the osteosarcoma has progressed or caused problems. To treat pain or control symptoms related to bone metastases, for example, interventional radiology procedures such as tumor ablation (radiofrequency or cryoablation) may be employed.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to A considerable number of cancer cases that are reported in Asia Pacific, with some of the region's nations having high incidence rates. The incidence of cancer in the area is influenced by a number of variables, including changes in lifestyle, alterations in the environment, and heightened cancer screening programs. Moreover the precision, effectiveness, and safety in cancer therapies are improved by the use of cutting-edge interventional oncology technology, including imaging modalities like MRI, CT, and ultrasound, in conjunction with cutting-edge instruments and equipment drives the growth of the market.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the region's well-established healthcare system, technology developments, and the rising desire for minimally invasive cancer therapies are the main drivers of the market. Furthermore the high incidence of cancer, the region's well-established healthcare system, technology developments, and the rising desire for minimally invasive cancer therapies are the main drivers of the market.

Key players in the market

Some of the key players profiled in the Interventional Oncology Market include AngioDynamics Inc., Cook Medical, HealthTronics Inc, Boston Scientific Corporation, Medtronic PLC, Terumo Corporation, Becton, Dickinson and Company, Merit Medical Systems Inc, Profound Medical Corp, IceCure Medical, Siemens Healthineers, Teleflex Incorporated, Medtronic Plc., Alpinion Medical Systems Co., IMBiotechnologies, Interface Biomaterials BV, Monteris Medical, Baylis Medical, Mermaid Medicals and Trod Medical

Key Developments:

In November 2023, Boston Scientific Corporation announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only U.S. Food and Drug Administration-cleared Intracept(R) Intraosseous Nerve Ablation System, a therapy to treat vertebrogenic pain that is a form of chronic low back pain.

In September 2023, Medtronic plc announced CE (Conformite Europeenne) Mark approval for its new all-in-one, disposable Simplera(TM) continuous glucose monitor (CGM) featuring a simple, two-step insertion process.

In July 2023, Purdue, IU and Cook Medical partner for 3-pronged approach to improve pediatric care. The Crossroads Pediatric Device Consortium will focus on meeting unmet needs for pediatric patients by accelerating the development, approval and availability of innovative medical devices for children.

Products Covered:

  • Ablation Devices
  • Embolization Devices
  • Support Devices

Indications Covered:

  • Hepatocellular Carcinoma
  • Osteosarcoma
  • Renal Cancer
  • Lung Cancer
  • Neuroendocrine Tumor
  • Glioblastoma Multiforme
  • Splenomegaly
  • Metastatic Colorectal Cancer
  • Other Indications

Procedure Types Covered:

  • Transcatheter Arterial Radioembolization
  • Transcatheter Arterial Chemoembolization
  • Thermal Tumor Ablation
  • Non-Thermal Tumor Ablation
  • Transcatheter Arterial Embolization
  • Other Procedure Types

End Users Covered:

  • Ambulatory Surgery Centers
  • Research & Academic Institutes
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Interventional Oncology Market, By Product

  • 5.1 Introduction
  • 5.2 Ablation Devices
    • 5.2.1 Cryoablation Devices
    • 5.2.2 Microwave Ablation Devices
    • 5.2.3 Radiofrequency (RF) Ablation Devices
    • 5.2.4 Other Ablation Devices
  • 5.3 Embolization Devices
    • 5.3.1 Non-Radio embolic Agents
      • 5.3.1.1 Microspheres
      • 5.3.1.2 Microparticles
      • 5.3.1.3 Coated Beads
      • 5.3.1.4 Drug Eluting Beads
    • 5.3.2 Radioembolic Agents
  • 5.4 Support Devices
    • 5.4.1 Guidewires
    • 5.4.2 Microcatheters

6 Global Interventional Oncology Market, By Indication

  • 6.1 Introduction
  • 6.2 Hepatocellular Carcinoma
  • 6.3 Osteosarcoma
  • 6.4 Renal Cancer
  • 6.5 Lung Cancer
  • 6.6 Neuroendocrine Tumor
  • 6.7 Glioblastoma Multiforme
  • 6.8 Splenomegaly
  • 6.9 Metastatic Colorectal Cancer
  • 6.10 Other Indications

7 Global Interventional Oncology Market, By Procedure Type

  • 7.1 Introduction
  • 7.2 Transcatheter Arterial Radioembolization
  • 7.3 Transcatheter Arterial Chemoembolization
  • 7.4 Thermal Tumor Ablation
  • 7.5 Non-Thermal Tumor Ablation
  • 7.6 Transcatheter Arterial Embolization
  • 7.7 Other Procedure Types

8 Global Interventional Oncology Market, By End User

  • 8.1 Introduction
  • 8.2 Ambulatory Surgery Centers
  • 8.3 Research & Academic Institutes
  • 8.4 Hospitals
  • 8.5 Other End Users

9 Global Interventional Oncology Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AngioDynamics Inc.
  • 11.2 Cook Medical
  • 11.3 HealthTronics Inc.
  • 11.4 Boston Scientific Corporation
  • 11.5 Medtronic PLC
  • 11.6 Terumo Corporation
  • 11.7 Becton, Dickinson and Company
  • 11.8 Merit Medical Systems Inc.
  • 11.9 Profound Medical Corp.
  • 11.10 IceCure Medical
  • 11.11 Siemens Healthineers
  • 11.12 Teleflex Incorporated
  • 11.13 Medtronic Plc.
  • 11.14 Alpinion Medical Systems Co.
  • 11.15 IMBiotechnologies
  • 11.16 Interface Biomaterials BV
  • 11.17 Monteris Medical
  • 11.18 Baylis Medical
  • 11.19 Mermaid Medicals
  • 11.20 Trod Medical

List of Tables

  • Table 1 Global Interventional Oncology Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Interventional Oncology Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Interventional Oncology Market Outlook, By Ablation Devices (2023-2034) ($MN)
  • Table 4 Global Interventional Oncology Market Outlook, By Cryoablation Devices (2023-2034) ($MN)
  • Table 5 Global Interventional Oncology Market Outlook, By Microwave Ablation Devices (2023-2034) ($MN)
  • Table 6 Global Interventional Oncology Market Outlook, By Radiofrequency (RF) Ablation Devices (2023-2034) ($MN)
  • Table 7 Global Interventional Oncology Market Outlook, By Other Ablation Devices (2023-2034) ($MN)
  • Table 8 Global Interventional Oncology Market Outlook, By Embolization Devices (2023-2034) ($MN)
  • Table 9 Global Interventional Oncology Market Outlook, By Non-Radio embolic Agents (2023-2034) ($MN)
  • Table 10 Global Interventional Oncology Market Outlook, By Microspheres (2023-2034) ($MN)
  • Table 11 Global Interventional Oncology Market Outlook, By Microparticles (2023-2034) ($MN)
  • Table 12 Global Interventional Oncology Market Outlook, By Coated Beads (2023-2034) ($MN)
  • Table 13 Global Interventional Oncology Market Outlook, By Drug Eluting Beads (2023-2034) ($MN)
  • Table 14 Global Interventional Oncology Market Outlook, By Radioembolic Agents (2023-2034) ($MN)
  • Table 15 Global Interventional Oncology Market Outlook, By Support Devices (2023-2034) ($MN)
  • Table 16 Global Interventional Oncology Market Outlook, By Guidewires (2023-2034) ($MN)
  • Table 17 Global Interventional Oncology Market Outlook, By Microcatheters (2023-2034) ($MN)
  • Table 18 Global Interventional Oncology Market Outlook, By Indication (2023-2034) ($MN)
  • Table 19 Global Interventional Oncology Market Outlook, By Hepatocellular Carcinoma (2023-2034) ($MN)
  • Table 20 Global Interventional Oncology Market Outlook, By Osteosarcoma (2023-2034) ($MN)
  • Table 21 Global Interventional Oncology Market Outlook, By Renal Cancer (2023-2034) ($MN)
  • Table 22 Global Interventional Oncology Market Outlook, By Lung Cancer (2023-2034) ($MN)
  • Table 23 Global Interventional Oncology Market Outlook, By Neuroendocrine Tumor (2023-2034) ($MN)
  • Table 24 Global Interventional Oncology Market Outlook, By Glioblastoma Multiforme (2023-2034) ($MN)
  • Table 25 Global Interventional Oncology Market Outlook, By Splenomegaly (2023-2034) ($MN)
  • Table 26 Global Interventional Oncology Market Outlook, By Metastatic Colorectal Cancer (2023-2034) ($MN)
  • Table 27 Global Interventional Oncology Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 28 Global Interventional Oncology Market Outlook, By Procedure Type (2023-2034) ($MN)
  • Table 29 Global Interventional Oncology Market Outlook, By Transcatheter Arterial Radioembolization (2023-2034) ($MN)
  • Table 30 Global Interventional Oncology Market Outlook, By Transcatheter Arterial Chemoembolization (2023-2034) ($MN)
  • Table 31 Global Interventional Oncology Market Outlook, By Thermal Tumor Ablation (2023-2034) ($MN)
  • Table 32 Global Interventional Oncology Market Outlook, By Non-Thermal Tumor Ablation (2023-2034) ($MN)
  • Table 33 Global Interventional Oncology Market Outlook, By Transcatheter Arterial Embolization (2023-2034) ($MN)
  • Table 34 Global Interventional Oncology Market Outlook, By Other Procedure Types (2023-2034) ($MN)
  • Table 35 Global Interventional Oncology Market Outlook, By End User (2023-2034) ($MN)
  • Table 36 Global Interventional Oncology Market Outlook, By Ambulatory Surgery Centers (2023-2034) ($MN)
  • Table 37 Global Interventional Oncology Market Outlook, By Research & Academic Institutes (2023-2034) ($MN)
  • Table 38 Global Interventional Oncology Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 39 Global Interventional Oncology Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.